Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N-methylglycine (Sarcosine) for Treatment of Major Depressive Disorder
Brief Summary: Major depressive disorder is a complex disease and most currently available antidepressants aiming at monoamine neurotransmission exhibit limited efficacy and cognitive effects. N-methyl-D-aspartate (NMDA), one subtype of glutamate receptors, plays an important role in learning and memory. N-methyl-D-aspartic acid (NMDA) enhancing agents, such as sarcosine (N-methylglycine), have been used as adjunctive therapy of schizophrenia. Sarcosine improved not only psychotic but also depressive symptoms in patients with schizophrenia. To confirm its antidepressant effect, the purpose of this study is to compare citalopram and sarcosine in efficacy for major depressive patients.


Options:
A: Arm Label: sarcosine; Type: EXPERIMENTAL; Interventions: Drug: sarcosine | Arm Label: citalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: citalopram | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): citalopram | Intervention Type: DRUG; Name: sarcosine; Assigned to Arm(s): sarcosine
B: Arm Label: Intranasal Esketamine plus oral antidepressant; Type: EXPERIMENTAL; Interventions: Drug: Esketamine, Drug: Duloxetine (Oral Antidepressant), Drug: Escitalopram (Oral antidepressant), Drug: Sertraline (Oral Antidepressant), Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant) | Arm Label: Placebo plus oral antidepressant; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Duloxetine (Oral Antidepressant), Drug: Escitalopram (Oral antidepressant), Drug: Sertraline (Oral Antidepressant), Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant) | Intervention Type: DRUG; Name: Esketamine; Assigned to Arm(s): Intranasal Esketamine plus oral antidepressant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus oral antidepressant | Intervention Type: DRUG; Name: Duloxetine (Oral Antidepressant); Assigned to Arm(s): Intranasal Esketamine plus oral antidepressant, Placebo plus oral antidepressant | Intervention Type: DRUG; Name: Escitalopram (Oral antidepressant); Assigned to Arm(s): Intranasal Esketamine plus oral antidepressant, Placebo plus oral antidepressant | Intervention Type: DRUG; Name: Sertraline (Oral Antidepressant); Assigned to Arm(s): Intranasal Esketamine plus oral antidepressant, Placebo plus oral antidepressant | Intervention Type: DRUG; Name: Venlafaxine Extended Release (XR) (Oral Antidepressant); Assigned to Arm(s): Intranasal Esketamine plus oral antidepressant, Placebo plus oral antidepressant
C: Arm Label: AZD6765 (150 mg) / Placebo; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: Placebo / AZD6765 (150 mg); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to AZD6765 | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): AZD6765 (150 mg) / Placebo | Intervention Type: DRUG; Name: Placebo to AZD6765; Assigned to Arm(s): Placebo / AZD6765 (150 mg)
D: Arm Label: Ketamine; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Propofol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): Propofol

Answer: A